Volume 67, Issue 6, Pages (June 2015)

Slides:

Advertisements

Similar presentations

Volume 72, Issue 1, Pages (July 2017)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 2, Pages (August 2015)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 53, Issue 4, Pages (April 2008)

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 65, Issue 5, Pages (May 2014)

Volume 70, Issue 4, Pages (October 2016)

Volume 60, Issue 6, Pages (December 2011)

Volume 70, Issue 2, Pages (August 2016)

Volume 71, Issue 5, Pages (May 2017)

Prostate Cancer Epidemic in Sight?

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 1, Pages (January 2013)

Volume 74, Issue 4, Pages (October 2018)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 67, Issue 2, Pages (February 2015)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 3, Pages (March 2015)

Volume 71, Issue 5, Pages (May 2017)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 6, Pages (December 2014)

Volume 74, Issue 2, Pages (August 2018)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Volume 63, Issue 3, Pages (March 2013)

Volume 62, Issue 4, Pages (October 2012)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 73, Issue 2, Pages (February 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 70, Issue 2, Pages (August 2016)

Volume 50, Issue 5, Pages (November 2006)

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

Volume 71, Issue 5, Pages (May 2017)

Antonio Alcaraz, Pierre Teillac European Urology Supplements

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 59, Issue 4, Pages (April 2011)

Volume 75, Issue 3, Pages (March 2019)

Volume 72, Issue 1, Pages (July 2017)

Volume 74, Issue 6, Pages (December 2018)

Volume 68, Issue 2, Pages (August 2015)

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Volume 53, Issue 2, Pages (February 2008)

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Volume 51, Issue 2, Pages (February 2007)

Volume 54, Issue 1, Pages (July 2008)

Presentation transcript:

Volume 67, Issue 6, Pages 1009-1016 (June 2015) The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy Zachary S. Zumsteg, Daniel E. Spratt, Paul B. Romesser, Xin Pei, Zhigang Zhang, William Polkinghorn, Sean McBride, Marisa Kollmeier, Yoshiya Yamada, Michael J. Zelefsky European Urology Volume 67, Issue 6, Pages 1009-1016 (June 2015) DOI: 10.1016/j.eururo.2014.09.028 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Prostate-specific antigen (PSA) recurrence-free survival in patients with National Comprehensive Cancer Network low-, intermediate-, and high-risk prostate cancer undergoing dose-escalated external beam radiotherapy. European Urology 2015 67, 1009-1016DOI: (10.1016/j.eururo.2014.09.028) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Incidence of (a) distant metastasis and (b) prostate cancer–specific mortality following biochemical failure. European Urology 2015 67, 1009-1016DOI: (10.1016/j.eururo.2014.09.028) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Incidence of distant metastasis and prostate cancer–specific mortality following biochemical failure, stratified by (a,b) a prostate-specific antigen doubling time (PSA-DT) cut-off point of 3.2 mo or (c,d) an interval to biochemical failure (IBF) cut-off point of 2.9 yr. European Urology 2015 67, 1009-1016DOI: (10.1016/j.eururo.2014.09.028) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 4 Incidence of (a) distant metastasis and (b) prostate cancer–specific mortality following biochemical failure, stratified by the number of unfavorable risk factors (RF). Unfavorable RFs were defined as a pretreatment Gleason score of 8–10, a pretreatment clinical tumor stage of T3b or T4, a posttreatment prostate-specific antigen (PSA) doubling time of <3 mo, or an interval to biochemical failure of <3 yr. European Urology 2015 67, 1009-1016DOI: (10.1016/j.eururo.2014.09.028) Copyright © 2014 European Association of Urology Terms and Conditions